NCT00051493已完成2 期
ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to evaluate the effects (good and bad) of LY231514 (ALIMTA) and Carboplatin on you and your non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •You have a diagnosis of non-small cell lung cancer.
- •You have received no prior chemotherapy.
- •You have at least one measurable lesion.
- •You have an adequate performance status.
- •You are at least 18 years of age.
排除标准
- •You have previously received chemotherapy for your lung cancer.
- •You have received radiation within the last 30 days.
- •You have active infection or other serious condition.
- •You have brain metastasis.
- •You have recently lost a significant amount of weight.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.Lung NeoplasmsNCT00051506Eli Lilly and Company
已完成
2 期
Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.Carcinoma, Non-Small-Cell LungNCT00061464Eli Lilly and Company48
已完成
2 期
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal MesotheliomaMesotheliomaNCT00061477Eli Lilly and Company48
已完成
2 期
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical TrialCarcinoma, Non-Small-Cell LungNCT00061451Eli Lilly and Company48
终止
2 期
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast CancerBreast CancerNCT00470249University of Southampton5